CSL – UBS rates the stock as Buy

By Broker News | More Articles by Broker News

Earnings reports from drug companies Merck and GSK showed strong growth for Gardasil and Cervarix, translating into around US$35m in royalties for CSL, in line with the broker’s expectations. Meanwhile, US industry data show strong IG growth is still evident.

The broker retains Buy and a $175 target for CSL.

Sector: Pharmaceuticals, Biotechnology & Life Sciences.

Target price is $175.00.Current Price is $170.60. Difference: $4.40 – (brackets indicate current price is over target). If CSL meets the UBS target it will return approximately 3% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →